Screening for lung cancer: A systematic review of overdiagnosis and its implications
Molecular Oncology · 2026-03 · 20 (3) · 611-628
DOI: 10.1002/1878-0261.70139 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Molecular Oncology, online erschienen am 11.11.2025. Verfasst von Fiorella Karina Fernández-Sáenz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain. Hauptthemen laut MEDLINE: Lung Neoplasms, Early Detection of Cancer, Overdiagnosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, European Commission, through the EU4Health Programme.
Abstract (Originalsprache)
Low‐dose computed tomography (LDCT) screening is increasingly used for early lung cancer detection targeted to high‐risk populations. Quantifying overdiagnosis, its potential harms, and economic consequences is important. We assessed the magnitude, harms, and economic impact of lung cancer overdiagnosis from LDCT screening in high‐risk populations. We synthesized evidence from eight randomized trials involving 84,660 participants. LDCT may increase overdiagnosis compared to no screening (relative risk [RR] 1.05; 222 additional cases per 100 000 people screened; low certainty). Compared to chest x‐ray (CXR), LDCT likely slightly increases overdiagnosis (RR 1.01; 63 additional cases per 100 000 people screened; moderate certainty). The proportion of overdiagnosed cancers is 0.07 (7000 more lung cancers overdiagnosed per 100 000 lung cancers detected; low certainty) when compared to no screening, and 0.01 compared to CXR (1000 more lung cancers overdiagnosed per 100 000 lung cancers detected; moderate certainty). In terms of cost, LDCT resulted in an additional societal burden of €2,026,422.00 per 100 000 individuals screened compared to no screening. The magnitude of overdiagnosis in LDCT screening is likely low compared to CXR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.
- Centro Cochrane Iberoamericano, Barcelona, Spain.
- Universidad Peruana Cayetano Heredia, Lima, Peru.
- Nottingham University Hospitals NHS Trust, UK.
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Netherlands.
- Wolfson Institute of Population Health, Quenn Mary University of London, UK.
ORCID-Profile: Mangesh Thorat, Ana Carolina Pereira Nunes Pinto
Förderung
- World Health Organization
- European Commission, through the EU4Health Programme
Zitieren
APA
Fernández-Sáenz, F. K., de la Torre-Perez, L., Baldwin, D. R., van der Aalst, C., Thorat, M., Ritchie, D., Carvalho, A. L., Espina, C., Solà, I., Canelo-Aybar, C., Pissinis, M. M., Alonso-Coello, P., & Pinto, A. C. P. N. (2026). Screening for lung cancer: A systematic review of overdiagnosis and its implications. Molecular Oncology, 20(3), 611-628. https://doi.org/10.1002/1878-0261.70139
Vancouver
Fernández-Sáenz FK, de la Torre-Perez L, Baldwin DR, van der Aalst C, Thorat M, Ritchie D, et al. Screening for lung cancer: A systematic review of overdiagnosis and its implications. Molecular Oncology. 2026;20(3):611-628. doi:10.1002/1878-0261.70139
BibTeX
@article{FernndezSenz2026,
author = {Fernández-Sáenz, Fiorella Karina and de la Torre-Perez, Laura and Baldwin, David R and van der Aalst, Carlijn and Thorat, Mangesh and Ritchie, David and Carvalho, Andre L and Espina, Carolina and Solà, Ivan and Canelo-Aybar, Carlos and Pissinis, Moira Magdalena and Alonso-Coello, Pablo and Pinto, Ana Carolina Pereira Nunes},
title = {Screening for lung cancer: A systematic review of overdiagnosis and its implications},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {3},
pages = {611--628},
doi = {10.1002/1878-0261.70139}
}
EUVIMED